louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04055298: Is Self-triage by Patients Using a Symptom-checker Safe?
Official title: Is Self-triage by Patients Using a Symptom-checker Safe?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Triage
Lead sponsor: in4medicine AG
Sponsor class: INDUSTRY
Collaborators: name: Cantonal Hospital of Baden
First posted: 2019-08-13
Enrollment: 2500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This is a prospective, non-randomized, no placebo-controlled interventional study.

The study aims to assess the safety of the web-based symptom checker SMASS-Triage and its tolerability in terms of incidence of under-triaged self-assessments and the potential risk to be life-threatening or harmful.

The patient's self-triage using a symptom checker will be compared with the urgency assessments conducted sequentially by three interdisciplinary panels of physicians (panel A, B and C). The risk assessments will be based on the structured reports generated by the symptom checker and the discharge summaries of the WIC/ED.


Eligibility criteria: Inclusion Criteria:

* All German-, French-, Italian-, English-speaking patients attending the WIC/ED are eligible.
* Informed Consent as documented by signature ( Informed Consent Form)
* Age 18-years and older
* Capable of judgment
* Not under tutelage

Exclusion Criteria:

* Patients with an Emergency Severity Index 1
* Leading complaint of the patient can't be found and assessed with the symptom checker
* Patients not being able to use a tablet-computer
* Patients not speaking German, French, Italian or English
* Minors under the age of 7-years
* Patients incapable of judgment
* Participants under tutelage
* Known or suspected non-compliance, drug or alcohol abuse,
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant

Primary outcomes:
measure: Proportion of self-triage assessed to be a hazardous under-triage
timeFrame: Baseline
Secondary outcomes:
measure: Proportion of self-triage with an over- or under-triage
timeFrame: Baseline
Other outcomes:
Locations:
city: Baden
country: Switzerland
facility: Cantonal Hospital Baden
state: Aarau
Study officials:
affiliation: in4medicine Ltd.
name: Andreas Meer, MD, MHIM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06937398: Survey on Patient and Parental Perceptions of EEG-monitoring During Paediatric Anaesthesia Care
Official title: Survey on Patient and Parental Perceptions of EEG-monitoring During Paediatric Anaesthesia Care
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Survey on Patient and Parental Perceptions of EEG-monitoring During Paediatric Anaesthesia Care
Keywords: EEG
Survey
Perception
Lead sponsor: KK Women's and Children's Hospital
Sponsor class: OTHER_GOV
First posted: 2025-04-22
Enrollment: 400
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All parents of children 1-16 years old and patients 12-16 years old coming for elective surgery requiring GA at KK Women's and Children's Hospital.

Brief summary: Electroencephalographic (EEG) monitoring during general anaesthesia (GA) is not typically part of standard care during GA. The recent availability of non-invasive commercial EEG monitors for children has made EEG monitoring more popular. Several studies have shown that monitoring EEG while under GA allows customization and titration of GA. However, the usefulness of EEG monitoring in children have not been established. It is a relatively new technology for some and will involve additional costs. The investigators aim to understand the perceptions of participants regarding EEG monitoring during paediatric anaesthesia care by administering a survey before and after GA.


Eligibility criteria: Inclusion Criteria:

* All parents of children 1-16 years old and patients 12-16 years old coming for elective surgery requiring GA at KK Women's and Children's Hospital will be invited to voluntarily participate in an electronic survey on Form SG.

Exclusion Criteria:

* Parents and patients coming for emergency surgery will not be invited for the survey.

Primary outcomes:
measure: Survey on patient and parental perceptions of EEG-monitoring during paediatric anaesthesia care
timeFrame: May 2022 until September 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: KK Women's and Children's Hospital
Study officials:
References:
citation: Bong CL, Ho D, Allen JC, Lim GS, Tan HK, Broekman BFP, Fabila T, Reddy S, Koh WP, Swee-Kim Tan J, Meaney M, Rifkin-Graboi A. Early Neurodevelopmental Outcomes Following Exposure to General Anesthesia in Infancy: EGAIN, a Prospective Cohort Study. J Neurosurg Anesthesiol. 2023 Oct 1;35(4):394-405. doi: 10.1097/ANA.0000000000000857. Epub 2022 May 26.
Clinical trial NCT05487898: Benefits of Cycling Wheelchair Training for Elderly With Physical Disability
Official title: Benefits of Cycling Wheelchair Training for Elderly With Physical Disability
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aged; Disable; Exercise; Rehabilitation; Wheelchair
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2022-08-04
Enrollment: 41
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To investigate the feasibility of cycling wheelchair training as an exercise for elderly disabled patients, and to determine its effects on cognition, quality of life, aerobic capacity and physiological markers. We measure SF-12. Other outcome measures included the Mini-Mental State Examination, Aero bike workload test, resting blood pressure (systolic and diastolic), and heart rate.


Eligibility criteria: Inclusion Criteria:

1. age \>65 years old
2. with a functional ambulation category scale (FAC) level 4 or below
3. muscle strength of both lower limbs was \>3 as the , or the muscle strength of one lower limb was 4 or above, as rated by the Medical Research Council Scale (MRC).

Exclusion Criteria:

1. hospitalized for acute medical problems within the past 3 months
2. having cardiopulmonary disease that could cause exercise hazards
3. unable to perform repetitive pedaling exercise due to diseases of the lower limbs
4. with pressure ulcers around hip area
5. with impaired cognitive function that did not allow completion of our questionnaires.

Primary outcomes:
measure: SF-12
timeFrame: one month
measure: MMSE questionnaire
timeFrame: one month
measure: Cycling ergometer
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
Study officials:
References:
Clinical trial NCT03693898: MR in Patients With Collagen VI Related Myopathies
Official title: MR in Patients With Neuromuscular Diseases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bethlem Myopathy
Ullrich Disease
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2018-10-03
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Collagen VI-related diseases include Bethlem myopathy and Ulrich dystrophy. They are both caused by decreased levels or a lack of collagen VI. The first symptoms can be present at birth as joint laxity and hypotonic muscles; often seen with luxation of the hip and scoliosis. During childhood, patients may develop contractures of fingers, wrists, elbows and ankles. Muscle weakness often appears in childhood to early adulthood and is progressive. It often results in walking difficulties.

There is no treatment available for Behtlem and Ulrich dystrophies.

The primary aim of this study is to investigate the pattern of involved muscles, the function and quality of the muscles and the disease severity using MRI.

Detailed description: See above

Eligibility criteria: Inclusion Criteria:

* confirmed Bethlem myopathy or Ulrich disease

Exclusion Criteria:

* All contraindications for undergoing an MRI scan

Primary outcomes:
measure: Muscle fat fraction
timeFrame: One MRI scan pr subject (exam lasts approximately 60 min)
Secondary outcomes:
measure: Muscle strength
timeFrame: Exam lasts approximately 40-60 min
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Copenhagen Neuromuscular Center
state: Østerbro
Study officials:
affiliation: CNMC, Rigshospitalet
name: John Vissing, Prof., MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00432198: Zolpidem Postmarketing Study in Adolescent Patients With Insomnia
Official title: Zolpidem Postmarketing Clinical Study: A Double Blind, Placebo Controlled Group Comparative Trial in the Adolescent Patients With Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Insomnia
Keywords: Insomnia
Zolpidem
Adolescent
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2007-02-07
Enrollment: 122
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the efficacy and safety of zolpidem for pediatric insomniacs in a randomized double blind-controlled trial


Eligibility criteria: Inclusion Criteria:

* patients diagnosed as having nonorganic insomnia of nonorganic sleep disorder in ICD10
* patients whose age at the time of obtaining consent is 12 years or over and 18 years or below

Exclusion Criteria:

* patients with schizophrenia or manic-depressive illness
* patients with insomnia caused by physical diseases
* patients having a history of hypersensitivity to zolpidem
* patients with attention-deficit hyperactivity disorder

Primary outcomes:
measure: Mean daily sleep latency for double-blind period
timeFrame: 2 Weeks
Secondary outcomes:
measure: Mean daily total hours of sleep
timeFrame: 2 Weeks
measure: Mean daily frequency of intermediate awaking
timeFrame: 2 Weeks
measure: Mean daily time of intermediate awaking
timeFrame: 2 Weeks
measure: Impression of patient for double-blind period
timeFrame: 2 Weeks
Other outcomes:
Locations:
city: Chubu region
country: Japan
city: Chugoku region
country: Japan
city: Hokkaido region
country: Japan
city: Kansai region
country: Japan
city: Kanto region
country: Japan
city: Kyushyu region
country: Japan
city: Shikoku region
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Use Central Contact
role: STUDY_CHAIR
References:
Clinical trial NCT02856698: MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Official title: Study Design and Rationale of "A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema": MIMO Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Acute Pulmonary Edema
Keywords: Acute heart failure
morphine
midazolam
in-hospital mortality
Lead sponsor: Hospital Universitario de Canarias
Sponsor class: OTHER
First posted: 2016-08-05
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been suggested as an alternative for morphine to relieving dyspnoea and anxiety in the patients with APE. The MIdazolan versus MOrphine in APE trial (MIMO) is a multicenter, prospective, open-label, randomized study designed to evaluate the efficacy and safety of morphine in patients with APE.


Eligibility criteria: Inclusion Criteria:

* Patients with acute pulmonary edema with dyspnoea and anxiety

Exclusion Criteria:

* Patients with known severe liver disease.
* Patients with known severe renal disease.
* Patients with expectation of death from other illness during the course of the trial.

Primary outcomes:
measure: In-hospital Mortality
timeFrame: 28 days after of the hospitalization
Secondary outcomes:
measure: Number of Participants That Required Invasive Mechanical Ventilation
timeFrame: Up to 1 week
measure: Length of Hospital Stay
timeFrame: Up to 30 days
Other outcomes:
Locations:
city: Córdoba
country: Spain
facility: Hospital Universitario Reina Sofía de Córdoba
state: Andalucía
city: Málaga
country: Spain
facility: Hospital Comarcal de la Axarquía
state: Andalucía
city: Barcelona
country: Spain
facility: Hospital Clínic i Provincial de Barcelona
state: Cataluña
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias
state: Santa Cruz De Tenerife
city: Alicante
country: Spain
facility: Hospital General de Alicante
city: Madrid
country: Spain
facility: Hospital Clínico Universitario San Carlos
city: Murcia
country: Spain
facility: Hospital General Universitario Reina Sofía
city: Málaga
country: Spain
facility: Hospital Comarcal de Axarquia
Study officials:
References:
Clinical trial NCT04096898: Senofilcon A Lenses in Moderate to Severe Dry Eye Disease
Official title: Clinical Trial to Determine Whether Senofilcon A Lenses Provide Relief of Symptoms and Signs in Patients With Moderate to Severe Dry Eye Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Moderate to Severe Dry Eye Disease
Keywords: dry eye
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
Collaborators: name: Johnson & Johnson Vision Care, Inc.
First posted: 2019-09-20
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A clinical trial using Senofilcon A daily lenses in the treatment of moderate to severe dry eye. This a comparison between signs and symptoms prior to and during treatment.

Detailed description: 32 patients with moderate to severe dry eye will be enrolled in this short-term proof of concept study to determine the efficacy in using soft lenses made of Senofilcon A in reducing signs and symptoms.

Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of moderate to severe dry eye associated with either Graft-versus-host disease (GVHD), Sjogren syndrome, idiopathic dry eyes, or minimal limbal cell deficiency
* A baseline Schirmer tear test (1) of less than 5 mm at 5 minutes without anesthesia
* Have a visual analog score for comfort of 50 or less (scale of 1-100, with 100 meaning perfect ocular comfort and 1 meaning severe ocular pain)
* Ability or the resources to insert and remove the study lenses
* An OSDI score greater than 42
* A willingness to sign an informed consent

Exclusion Criteria:

* No dry eyes or mild dry eyes
* A baseline Schirmer tear test (1) of greater than 5 mm of wetting at 5 minutes
* Dry eye comfort score of greater than 50 on a visual analog scale
* Unable to insert or remove the study lenses (or have a family member do so)
* Have an OSDI score less than 42
* Has been diagnosed with neurotrophic keratopathy in either eye
* Unwilling to enroll in the study, and unwilling to provide signed informed consent to participate in the study

Primary outcomes:
measure: Ocular Surface Disease Index (OSDI)
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Illinois at Chicago
state: Illinois
Study officials:
References:
Clinical trial NCT01314898: A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers
Official title: A Phase 1, Double-Blind (Sponsor-Open), Placebo- And Active-Controlled, Single Dose, Crossover Study To Assess Antimineralocorticoid Activity Of Oral Pf-03882845 In Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Keywords: Single dose
cross-over
active-control
placebo control
antimineralocorticoid activity
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2011-03-15
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: 24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845 can be established following single oral doses.


Eligibility criteria: Inclusion Criteria:

* Male and/or female healthy volunteers, age 18 to 55 years. Females must be of non-childbearing potential.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).
* Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, diet restrictions and other trial procedures.

Exclusion Criteria:

* Subjects with a supine BP \>140 mm Hg systolic or \>90 mm Hg diastolic or \<100 mm Hg systolic or \<60 mm Hg diastolic based on the average of the triplicate
* Serum potassium \>=5.1 mmol/L or \<3.5 mmol/L at screening, confirmed by a single repeat if deemed necessary.
* Estimated GFR \<60 mL/min/1.73 m2 using the Cockcroft-Gault formula measurement of the individual parameters following at least 5 minutes of rest at Screening.

Primary outcomes:
measure: Twenty-four hour urinary Na/K ratio (AUC(0-24)).
timeFrame: 0-24hr postdose per period
Secondary outcomes:
measure: Area Under the Curve(AUClast) from the time of dosing to the last data point of PF-03882845.
timeFrame: 0-24 hr post dose per period
measure: Time of Maximum concentration(Tmax) of PF-03882845.
timeFrame: 0-24 hr post dose per period
measure: Maximum concentration (Cmax) of PF-03882845.
timeFrame: 0-24 hr post dose per period
measure: Safety and tolerability: Physical examinations, adverse event monitoring, clinical safety laboratory assessments, vital sign measurements and 12-lead ECGs.
timeFrame: 2 months
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06908798: Fecal Calprotectin for Prediction of Esophageal Varices in Cirrhotic Patients
Official title: The Accuracy of Fecal Calprotectin in Detecting Esophageal Varices in Egyptian Patients With Liver Cirrhosis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Esophageal Varices
Keywords: Fecal calprotectin
esophageal varices
liver cirrhosis
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-04-03
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This cross-sectional observational study will be carried out on 156 patients who will be enrolled from the endoscopy unit in the Tropical Medicine and Infectious Diseases Department, Tanta University Hospital, Egypt. The start of research will begin in December 2024 and will end in December 2025.

Brief summary: The goal of this cross-sectional observational study is to evaluate the accuracy of fecal calprotectin versus non-invasive scores in assessing the presence and grading of esophageal varices in Egyptian patients.

Researchers will compare fecal calprotectin levels in cirrhotic patients with and without esophageal varices (EVs) and healthy subjects. researchers will also evaluate the performance of fecal calprotectin, AST to platelet ratio index (APRI) score, fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) score, platelet-albumin-bilirubin (PALBI) score, and platelet-spleen diameter ratio (PSR) for predicting esophageal varices.

Participants will undergo history-taking, clinical examination, laboratory investigations, fecal calprotectin, abdominal ultrasonography, and upper endoscopy. Endoscopic grading of esophageal varices will be done using Paquet's classification. The APRI, FIB-4, ALBI, PALBI, and PSR scores will be calculated. The performance of fecal calprotectin for predicting EVs will be compared versus other non-invasive scores.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Liver cirrhosis

Exclusion Criteria:

* Patients aged \< 18 years.
* Inflammatory bowel disease.
* Infectious gastroenteritis.
* Malignancy.
* Patients on proton pump inhibitors or NSAID.
* Patients with spontaneous bacterial peritonitis.
* Patients with hepatic encephalopathy.
* Unwilling to participate in our study.

Primary outcomes:
measure: measuring fecal calprotectin level (microgram/gram) for predicting esophageal varices
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: comparing fecal calprotectin versus non-invasive scores for predicting esophageal varices
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University Hospitals
state: Gharbyea
Study officials:
affiliation: Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
name: Rania M Elkafoury, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00933998: Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®
Official title: Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Peripheral Neuropathy
Keywords: DPN
Lead sponsor: Carolina Musculoskeletal Institute
Sponsor class: OTHER
Collaborators: name: Pamlab, L.L.C.
name: Baylor University
First posted: 2009-07-08
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to determine if Metanx improves sensory neuropathy in persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a physician. It consists of L-methylfolate, Pyridoxal 5'-phosphate, and Methylcobalamin, which are the active forms of folate, vitamin B6, and vitamin B12, respectively. Subjects will be assigned to receive Metanx for 12 months. Baseline quantitative sensory testing will be done before the patient receives Metanx. Additional quantitative sensory testing will be done at 6 and 12 months to evaluate.


Eligibility criteria: Inclusion Criteria:

* Consecutive diabetic patients entering the office (private practice)
* Subjective symptoms of numbness, burning, paresthesia, etc.
* Failed Monofilament of at least two points on each foot
* Abnormal PSSD study
* Willing to participate in protocols or study

  * Taking one Metanx tablet bid for 2 weeks then one Metanx tablet daily
  * Keep scheduled appointments for follow up studies
  * Report any other medical interventions, studies, or medication changes
  * Report any problems of medical or psycho-social matters to investigators
  * HgbA1c NOT monitored or specific value required for participation

Exclusion Criteria:

* History of back problems (Surgery or ECSI) or other large fiber neuropathies
* History of chemotherapy
* History of chemical exposure

Primary outcomes:
measure: Epidermal Nerve Density Count
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Aiken
country: United States
facility: Carolina Musculoskeletal Institute
state: South Carolina
Study officials:
References: